Clinical Trial Update: Study Evaluating Sirolimus (Rapamune™) in Solid Organ Transplant Recipients [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating sirolimus (Rapamune) in solid organ transplant recipients has completed. The listed conditions include graft-versus-host disease and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Kidney Transplantation

Drugs mentioned

• Rapamune (sirolimus)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Graft vs Host Disease, Kidney Transplantation | Phase 3 | Status: COMPLETED